Dewey McLin III, PhD

Dewey McLin, PhD, serves as Vice President, Medical Affairs for Longobard Pharmaceuticals, supporting the development of treatments for rare neurological conditions, including bexicaserin for the treatment of seizures associated with developmental and epileptic encephalopathies. With nearly two decades in the pharmaceutical industry, Dr. McLin’s areas of expertise are in Medical Affairs, new product development, orphan diseases, specialty pharmacy products, global product launches, and supporting the transition of organizations from R&D to commercialization. He earned a doctorate degree and subsequently held an adjunct faculty position at the University of California, Irvine in Neurobiology and Behavior. Dr. McLin has held affiliate faculty positions at the University of California, San Diego, Chapman University, and the University of Texas at Austin College of Pharmacy.